Rajesh Malik Sells 3,776 Shares of G1 Therapeutics Inc (NASDAQ:GTHX) Stock

Share on StockTwits

G1 Therapeutics Inc (NASDAQ:GTHX) insider Rajesh Malik sold 3,776 shares of G1 Therapeutics stock in a transaction on Monday, September 17th. The stock was sold at an average price of $66.08, for a total value of $249,518.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

GTHX stock traded down $0.02 during trading on Friday, hitting $42.98. The stock had a trading volume of 279,513 shares, compared to its average volume of 278,142. G1 Therapeutics Inc has a 1-year low of $18.03 and a 1-year high of $69.57. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of -12.04 and a beta of -1.02.

G1 Therapeutics (NASDAQ:GTHX) last announced its earnings results on Wednesday, August 8th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.01. On average, sell-side analysts predict that G1 Therapeutics Inc will post -2.68 EPS for the current year.

A number of hedge funds have recently made changes to their positions in the stock. FMR LLC raised its stake in G1 Therapeutics by 1.2% in the 2nd quarter. FMR LLC now owns 4,902,732 shares of the company’s stock valued at $213,073,000 after purchasing an additional 57,156 shares during the last quarter. BlackRock Inc. raised its stake in G1 Therapeutics by 32.0% in the 2nd quarter. BlackRock Inc. now owns 1,690,360 shares of the company’s stock valued at $73,462,000 after purchasing an additional 409,300 shares during the last quarter. Bank of New York Mellon Corp raised its stake in G1 Therapeutics by 1,497.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,262,991 shares of the company’s stock valued at $54,890,000 after purchasing an additional 1,183,940 shares during the last quarter. Voya Investment Management LLC raised its stake in G1 Therapeutics by 7,889.9% in the 2nd quarter. Voya Investment Management LLC now owns 449,834 shares of the company’s stock valued at $19,550,000 after purchasing an additional 444,204 shares during the last quarter. Finally, BB Biotech AG acquired a new position in G1 Therapeutics in the 2nd quarter valued at about $15,324,000. 69.17% of the stock is owned by hedge funds and other institutional investors.

GTHX has been the subject of several research reports. BidaskClub raised G1 Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, June 16th. Zacks Investment Research downgraded G1 Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 11th. Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a research note on Thursday, August 9th. JPMorgan Chase & Co. lifted their price target on G1 Therapeutics from $58.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, August 10th. Finally, BTIG Research initiated coverage on G1 Therapeutics in a research note on Monday, September 10th. They set a “buy” rating and a $80.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $74.50.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Recommended Story: Determine Your Level of Risk Tolerance

Insider Buying and Selling by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.